Xience or Vision Stent Management of Angina in the Elderly

Multi-centre, Randomised,Prospective Trial of Xience or Vision Stent, Management of Angina in the Elderly

The treatment of complex coronary disease causing limiting symptoms of angina with drug-eluting stent technology will prove superior to bare metal stent technology, with respect to a combined endpoint of mortality, MI, requirement for target vessel revascularisation and severe haemorrhage, in patients aged 80 or above.

Inclusion Criteria:

• AGE>80
• Stable angina or acute coronary syndrome
• Coronary narrowing suitable for stenting that is either ≥15mm long and/or ≤3mm diameter.
• Any lesion with high risk of restenosis eg chronic total occlusion, bifurcation, severe calcification
• Any left main stem lesion

Exclusion Criteria:

• Acute ST segment elevation myocardial infarction
• Cardiogenic shock
• Platelet count =50 x 109/mm3
• Patient life expectancy < 1 year
• Known allergies to clopidogrel, aspirin, heparin, stainless steel, IV contrast or stent drug elutant
• Recent major GI haemorrhage (within 3 months)
• Any previous cerebral bleeding episode
• Participation in another investigational drug or device study
• Patient unable to give consent
• Clinical decision precluding the use of drug eluting stent